Switching from artisanal CBD to Epidiolex for children with Dravet or Lennox Gastaut syndrome
Treatments studied
Part of Brain & nervous system, Genetic & congenital clinical trials.
This study looks at what happens when children with Dravet or Lennox Gastaut syndrome switch from a homemade or artisanal CBD product to Epidiolex, a prescription CBD. The goal is to see if the switch is safe and helps control seizures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 2 and 18 years old.
- You have a diagnosis of Dravet or Lennox Gastaut syndrome.
- You have been taking a stable dose of an artisanal CBD product (5–20 mg per kg per day) for at least 3 months.
- Your artisanal CBD product has a high CBD to THC ratio (at least 20:1).
- You are also taking at least one other seizure medicine.
- You have not been on Epidiolex before.
- You are willing to keep a seizure diary.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a skin patch that delivers CBD (a substance from cannabis) to treat seizures in people with Dravet syndrome or Lennox-Gastaut syndrome. The patch is placed on the skin, and the study looks at whether it is safe and helpful.
This trial tests a new type of brain stimulation (adaptive deep brain stimulation) that adjusts in real time to stop seizures in children with Lennox-Gastaut syndrome. It's for children who haven't gotten enough help from medications and have frequent drop seizures.
This trial tests a way of slowly increasing the dose of a CBD medicine (called Epidiolex) in adults with a severe type of epilepsy called Lennox-Gastaut syndrome (LGS). The goal is to find the best, most comfortable dose that helps reduce seizures.
This trial tests an oral cannabidiol medicine (Epidiolex) for children whose seizures are not controlled by other treatments. It aims to see if adding this drug can reduce seizure frequency.
This trial provides access to cannabidiol (CBD), a marijuana-derived compound, for children with severe epilepsy that hasn't improved with standard medications. The goal is to see if CBD can help reduce seizures in this difficult-to-treat group.
This study tests whether starting the medication Epidiolex (a purified form of cannabidiol) before any seizures occur can help prevent or delay seizures in infants with Sturge-Weber syndrome.
Hear when a new Lennox Gastaut Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.